WO2025262623 - METHOD OF TREATING HBV/HIV COINFECTION
National phase entry is expected:
Publication Number
WO/2025/262623
Publication Date
26.12.2025
International Application No.
PCT/IB2025/056231
International Filing Date
18.06.2025
Title **
[English]
METHOD OF TREATING HBV/HIV COINFECTION
[French]
MÉTHODE DE TRAITEMENT D'UNE COINFECTION PAR VHB/VIH
Applicants **
GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
Inventors
PAFF, Melanie T.
THEODORE, Dickens
HEZAREH, Marjan
BOURNE, Eric J.
DOLMAN, Grace E.
Priority Data
63/662,597
21.06.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3062 | |
| EPO | Filing, Examination, Granting | 27253 | |
| Japan | Filing, Examination, Granting | 3291 | |
| South Korea | Filing, Examination, Granting | 4252 | |
| USA | Filing, Examination, Granting | 13340 |
Total:
51,198
Contact Us
Abstract[English]
The present disclosure is related to methods for treating chronic hepatitis B infection in a human having HBV/HIV coinfection. The methods comprise administering to a human having HBV/HIV coinfection a therapeutically effective amount of an antisense oligonucleotide (ASO), wherein the subject has a HBsAg baseline level of not greater than a threshold level.[French]
La présente divulgation concerne des méthodes de traitement d'une infection chronique par l'hépatite B chez un être humain ayant une coinfection par VHB/VIH. Les méthodes comprennent l'administration à un être humain ayant une co-infection par VHB/VIH d'une quantité thérapeutiquement efficace d'un oligonucléotide antisens (ASO), le sujet ayant un niveau de base de HBsAg non supérieur à un niveau seuil.